Richard Jelinek
nominated to join the Board; current director David Farner to depart the Board in June 2023, in addition to previously announced
departure of Frank Williams.
WASHINGTON, April 19,
2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE:
EVH), a health care company that delivers proven specialty clinical
solutions to payers and providers, today announced that a new
director nominee will stand for election to the Board of Directors
at the annual meeting of stockholders scheduled to be held on
June 8, 2023.
The Board has recommended Mr. Richard
Jelinek for election at the annual meeting. Mr. Jelinek is
currently a managing partner at Czech One Capital Partners. Rick
was executive vice president at Aetna, Inc. before becoming executive vice
president of enterprise modernization and integration for CVS
Health. Prior to his position at Aetna, Rick was the chief executive officer of
OptumHealth.
"I am honored to be nominated to join Evolent's board," said Mr.
Jelinek. "I believe Evolent is well-positioned for market
leadership in value-based specialty care, and I look forward to
supporting the mission in the years to come."
"Rick is a highly respected leader in the health care industry,
and we are excited about the opportunity to have him join our
board," said Evolent Chair of the Board Ms. Cheryl Scott.
"Independent perspectives from industry leaders like Rick are
important to the continued evolution of our board," said Evolent
Chief Executive Officer and Co-Founder Seth
Blackley. "We believe the company will benefit from his
perspectives as we accelerate our leadership in value-based
specialty care."
Evolent concurrently announced that Mr. David Farner tendered his resignation from the
Board, pursuant to the stockholder's agreement between Evolent and
the University of Pittsburgh Medical
Center (UPMC). Mr. Farner — a UPMC designated director — will serve
out the remainder of his current term through Evolent's annual
meeting in June. Mr. Farner's departure from the Board is in
addition to the previously announced departure of former Chairman
and CEO Frank J. Williams, an
Evolent co-founder. Mr. Williams will retire from the Board also in
June.
"I want to thank David and Frank for their dedication and
contributions to Evolent and the Board," said Ms. Scott. "We
appreciate their partnership over the years and the work they've
done to help position Evolent for future success."
Mr. Jelinek has served as managing partner at Czech One Capital
Partners since 2020. He was executive vice president at
Aetna, Inc. before becoming
executive vice president of enterprise modernization and
integration for CVS Health. Prior to that, Mr. Jelinek held various
executive leadership roles at UnitedHealth Group and successor
companies from 1994 to 2013, including CEO of OptumHealth. He
received an MHSA and an MBA from the University of Michigan and a B.S. in Business
Administration from the University of Southern
California.
About Evolent Health
Evolent (NYSE: EVH) specializes in better health outcomes for
people with complex conditions through proven solutions that make
health care simpler and more affordable. Evolent serves a national
base of leading payers and providers and is consistently recognized
as a top place to work in health care nationally. Learn more about
how Evolent is changing the way health care is delivered by
visiting evolenthealth.com.
Important Additional Information and Where to Find
it
Evolent Health, Inc. (the "Company") intends to file a
proxy statement with the Securities and Exchange Commission (the
"SEC") in connection with the solicitation of proxies for the
Company's 2023 Annual Meeting of Stockholders (the "Proxy
Statement" and such meeting the "Annual Meeting"). The Company, its
directors and certain of its executive officers will be
participants in the solicitation of proxies from shareholders in
respect of the Annual Meeting. Information regarding the names of
the Company's directors and executive officers and their respective
interests in the Company by security holdings or otherwise are set
forth in the Company's proxy statement for the 2022 Annual Meeting
of Stockholders, filed with the SEC on April
29, 2022 (the "2022 Proxy Statement"). To the extent
holdings of such participants in the Company's securities have
changed since the amounts described in the 2022 Proxy Statement,
such changes have been reflected on Initial Statements of
Beneficial Ownership on Form 3 or Statements of Changes in
Beneficial Ownership on Form 4 filed with the SEC. Details
concerning the nominees of the Company's Board of Directors for
election at the Annual Meeting will be included in the Proxy
Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND
SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT
DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE
COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and
shareholders will be able to obtain a copy of the definitive Proxy
Statement and other documents filed by the Company free of charge
from the SEC's website, www.sec.gov. The Company's shareholders
will also be able to obtain, without charge, a copy of the
definitive Proxy Statement and other relevant filed documents by
directing a request by mail to Evolent Health, Inc., Attention:
Investor Relations, 800 N. Glebe Road, Arlington, VA 22203, or from the Company's
website, www.evolenthealth.com.
Contacts:
Seth R.
Frank
Vice President, Investor Relations
Evolent Health, Inc.
sfrank@evolenthealth.com
571-895-3919 (W)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evolent-health-names-new-independent-nominee-for-election-to-board-of-directors-301802280.html
SOURCE Evolent Health